Patent Oppositions in vaccines and immunity drugs industry

Explore the competitive field of vaccines and immunity drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in vaccines and immunity drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the vaccines and immunity drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the vaccines and immunity drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Binding Molecules For Bcma And Cd3AMGENAug 26, 2026REGENERON PHARMACEUTICALS
Method And Compositions For Cellular ImmunotherapyFRED HUTCHINSON CANCER CENTERAug 26, 2026EIP
Improved Method For Producing Antibody-Drug ConjugateDAIICHI SANKYOAug 25, 2026SANDOZ
Antibody-Containing PreparationCHUGAI SEIYAKU KABUSHIKI KAISHAAug 19, 2026KERNEBECK PATENTANWALTS
Antibody-Containing PreparationCHUGAI SEIYAKU KABUSHIKI KAISHAAug 18, 2026STRAWMAN
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHMEAug 17, 2026WUESTHOFF & WUESTHOFF
Antibody-Containing PreparationCHUGAI SEIYAKU KABUSHIKI KAISHAAug 7, 2026MAIWALD PATENTANWALTS
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 29, 2026STORZ
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 28, 2026DEVA HOLDING
Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBBJul 27, 2026GREINER

To stay ahead in the competitive vaccines and immunity drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the vaccines and immunity drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Mar 11, 2015Treatment Of Tnf Alpha Related DisordersABBVIE BIOTECHNOLOGY13
Jan 18, 2017Methods Of Administering Anti-Tnfalpha AntibodiesABBVIE BIOTECHNOLOGY11
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB11
Feb 17, 2021Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLUDWIG MAXIMILIANS UNIVERSITT MNCHEN11
Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI11
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALS10
Feb 22, 2017Combination Therapies Employing Gitr Binding MoleculesTOLERX10
Oct 29, 2025Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)BRISTOL MYERS SQUIBB10
Oct 22, 2014Method For Treating Joint DamageBIOGEN IDEC9
May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHE9